Examples Of Infinite Affinity For Applications In Bioconjugations Pdf Download
Abstruse
Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past xxx years due to the lack of early on theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for float cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the broad use of the targeting peptides for intravesical theranostic techniques in float cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical awarding.
Introduction
Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary organisation in Chinese male person population with loftier potential of recurrence and progression up to 21–31% and 0.viii–three.8%, respectively [1]. Currently a confirmed diagnosis of BCa mainly relies on cystoscopy or transurethral resection of bladder tumor combined with pathological test [ii]. On some occasion where non-muslce BCa (NMIBC) is of highly aggressive type, long-term intravesical is strongly recommended [two]. Therefore, at least 80% of BCa population benefit from the intravesical theranostic technique. Yet, both the surveillance of transurethral endoscope and intravesical therapy are lack of tumor specificity. Hence, carcinoma in situ or singular hyperplasia tin can be ignored on the vision of white light cystoscopy, and drugs intravesically administrated can not be concentrated in the cancerous lesion. The key to improve the efficacy of intravesical theranostic technique is to equip itself with targeting agent.
The currently used targeting agents can exist mainly categorized into nucleic acid aptamers, antibodies, and peptides. Nucleic acid aptamers tin exist screened out to target many types of elements, including inorganic and organic small molecules, biological macromolecules, and even cells. But it is sometimes challenging to obtain nucleic acid aptamers with loftier specificity and loftier affinity for individual targets [three]. Due to the electronegative nature of the nucleic acid aptamers, the binding analogousness for electronegative target wanes [4]. Its binding analogousness also requires certain ionic strength, pH, and so along [4]. The antibody exhibits good performance in good specificity, but its value is discounted by its obvious toxicity to normal tissues [v], poor penetration into tumor tissues [half-dozen, 7], and loftier cost of prodcution. The targeting peptide commonly composes of no more than 100 monomeric amino acids. The cost of production is lower compared to that of antibodies. The high binding affinity can be maintained in harsh conditions. Also, the lower molecular weight of the targeting peptide adamant its facilitated elimination from nonspecific targeting tissues at the concentration of nanomolar. From the perspective of stability, specificity and economic cost, the targeting peptide is more potential to be used for alter the intravesical theranostic technique. Notwithstanding, no systematic review has covered the wide utilise of the targeting peptides for intravesical theranostic techniques in Bca. Herein, all aspects of the targeting peptides for Bca is introduced, including the peptide screening, the targeting mechanism, and its preclinical application.
Screening of Peptide
Phage-Displayed Peptide Libraries
One of the most widely used peptide screening technology is phage-displayed technology, featured past its high efficiency and low toll. Smith first proposed this technology in 1985 [8]. The mechanism backside this tin can be simplified as a combination of the genetic engineering engineering and the peptide library with phage. In 1990, Scott and Smith successfuly introduced the fusion protein gIII containing random sequence peptides on the phage surface [nine] to consummate a phage surface display peptide library. Specifically, it is necessary to insert a chemically synthesized random oligonucleotide sequence into the gene encoding the phage glaze protein to express various random brusk peptides Table i. Then, the phages were panned for float tumor cells, and phages that specifically bind to float tumors were screened out. Dilate the DNA insert of the phage clone by polymerase chain reaction (Polymerase Chain Reaction, PCR), and sequence the Dna insert to catechumen it into the corresponding peptide sequence. The phage-displayed technology was used to screened out many types of BCa-targeting peptides, including P4 peptide, Bld-ane peptide, CLT1 peptide, and NYZL1 peptide [10,11,12,thirteen].
One-Bead One-Compound Combinatorial Peptide Library Engineering science
The one-bead, one-peptide synthesis method is another peptide screening technology. I resin dewdrop serves as a carrier, loading with a peptide of one sequence, and the One dewdrop and ane peptide (a resin bead contains a peptide sequence) are synthesized using resin as a carrier and co-ordinate to the mixing-equalization method Table 2. After each step is connected to the resin, information technology is insoluble in the solvent, causing impurities. Excess reagents are easy to remove. Afterwards screening and sequencing of the obtained peptide library, the peptide structure can be obtained [14, 15]. The principle of the one-dewdrop one-peptide library fabricated by the mixing-equalization method is to outset connect the protected amino acids to the resin, such as x kinds of amino acids, subsequently existence mixed and deprotected, they are divided into ten groups, and each group has ten kinds connected to the resin. Then, ten protected amino acids are used to couple with each grouping to obtain x × 10 dipeptides (continued with resin), and the resulting dipeptides are mixed and divided into ten groups evenly. After repeating the above steps, 10X10X10 peptides can exist obtained. And then use the established peptide library to develop tumor-specific targeting peptides. Simultaneously screen millions of beads (each bead is a unique peptide sequence) to identify peptides bound to tumor cell surface molecules. We can use an enzyme-linked colorimetric method like to western blot or observe the cells attached to the beads' surface to screen for "positive chaplet" with specific ligands. The PLZ4 peptide was obtained by co-cultivating the one-bead-ane-peptide library with BCa cells after two-round screening, and has high analogousness to BCa cells equally proved in T24, 5637, and TCCSUP jail cell lines [16].
Derived Peptide
The targeting peptide can also be a course of a natural ligand or a peptide derivative, such every bit pH low insertion peptide (pHLIP peptide). pHLIP is a h2o-soluble polypeptide derived from helix C of bacteriorhodopsin, and tin can insert into the cell membrane to form a stable transmembrane α-helix at the acidic tumor microenvironment [17]. Similarly, NT-iv peptide is a iv-branched peptide containing human neurotensin sequence with curt retention period in the circulation [xviii]. For prolonged circulation retentivity, several types of neurotensin analogs accept been developed [xix,20,21], and much more full-bodied accumulation in BCa tissues was verified [18].
Fibronectin Attachment Poly peptide (FAP) is a member of the fibronectin-binding glycoprotein family unit, and plays an essential function in the process of Bacillus Calmette-Guérin adhesion to BCa. The functional, agile region of FAP is located in sequence 269–280, and the bounden sequence is RWFV [22].
The purified HIV nuclear trans activating factor (TAT), a classical type of the cell-penetrating peptide (CPP), tin be spontaneously internalized into the cell without a transfection agent in the prison cell medium [23]. The arginine-rich fragment in the 48–lx sequence of TaT protein is a crucial component to break through the membrane barrier independent of the receptor-mediated and the energy-dependent endocytosis pathway [24]. Arginine polymers composing of xi arginines (R11) mimics the active part of the TAT peptide, and targets BCa specifically rather than other tumors [25].
Peptide Targeting Machinery
Tumor Microenvironmental Response
Tumor cells are mainly metabolized past aerobic glycolysis to meet a strong energy demand, leading to the accumulation of the metabolic product lactic acid and the decreased pH value of the tumor tissue area existence 0.iii–0.7 U lower than normal tissues [26]. The pHLIP peptide is sensitive to targeting in an acidic environs and can detect changes in the body from 0.2–0.three pH units [27, 28]. The acidic environment caused by the high metabolism of bladder tumors meets the conditions for specific targeting of PHLIP. For pHLIP, the reduced pH triggered the protonation of Asp rest and the increased hydrophobicity of the peptide concatenation. Nether this condition, pHLIP can form its spiral construction easily across the bilayer membrane [29]. Studies on clinical specimens take confirmed the specific targeting of PHLIP to the acidic surroundings of bladder tumors [30].
Receptor and Ligand Interaction
The cyclic peptide PLZ4 (amino acrid sequence cQDGRMGFc) can binds to Bca cells specifically through the strong binding between the (D/Due north) GR motif and ανβ3 integrin [31]. When using U87 (human glioma cells) and MDA-231 (human being chest cancer cells), both of which expresses high level of ανβ3 integrin [32], the amounts of PLZ4 internalized by U87 was college than that in MDA-231. The results indicates more significant expression difference of glycosylation or integrin between normal urinary tract cells and BCa cells [x]. Furthermore, five amino acids, X2 (D), X4 (R), X7 (F), X3, and X6 (G) are proven to exist critical amino acids for tumor-specific bounden.
The P4 peptide sequence (NVFTVSP) shares the like sequence with the conserved region of FGFR3c, and is expected to block the interaction between FGF9 and FGFR3c. The abnormal expression of FGF9 loftier-affinity receptor FGFR3c is closely related to the tumorigenesis and progression of BCa [33,34,35]. Thus, the P4 peptide is potential for inhibiting the downstream pathway of FGFR3c.
Other Targeting Mechanisms
Among all CPPs, R11 is the best candidate for BCa-targeting regardless of the cell multifariousness [36]. But the mechanism remains to be explored. The loftier amount of phosphatidylserine and the overexpressed glycoprotein located on the outer surface of the BCa cell membrane might contributed to its targeting effiency.
The CLT1 peptide gains the ability to target the BCa in the presence of a urothelial tumor matrix component fibronectin, and and then the cellular internalization can be driven through the α5β1 integrin and chloride intracellular channel three (CLIC3). For the purpose of CLT1 internalization, the origin of fibronectin appears to exist irrelevant, as both plasma fibronectin, cellular fibronectin and urine fibronectin are able to work [37].
Neurotensin-quadruple neurotensin peptide (NT4) is a derivative of Neurotensin, and its branched construction protects it from the proteolysis and brings enhanced biological activity [38]. In vitro cell lines and tissue specimen proved the BCa-targeting property of NT4, but whether the neurotensin receptor is the existent bounden site remains unknown, as the neurotensin receptor coexist under the urothelial and in the smooth muscle layer.
Application of Peptides
The Diagnostic Effect of Peptides on Bladder Tumors
Combining the BCa-targeting peptide with fluorescein or imaging agents enable more precise visualization of BCa in dissimilar modalities.
pHLIP conjugated with a almost-infrared fluorescent dye [indocyanine greenish (ICG)] targets low extracellular pH, allowing visualization of cancerous lesions in human bladder carcinoma ex vivo. Cystectomy specimens obtained after radical surgery were irrigated with a solution of the ICG pHLIP construct, and the fluorescence spot image was nerveless to establish the correlation between ICG pHLIP imaging and histopathological analysis. The detection sensitivity is 97%. The specificity is 100%, but reduced to 80% when transurethral resections or chemotherapy is applied prior to the CG pHLIP imaging [39].
R11, as an unique BCa-targeting CPP, is used to functionalize the superparamagnetic iron oxide particles (SPIO) to meliorate the MR imaging contrast. Results from Prussian bluish staining and TEM revealed that SPIO-R11 were efficiently taken up by BCa cells rather than normal urothelial cells, and in vitro MRI studies showed that SPIO-R11 greatly increased MR imaging contrast over the SPIO in BCa cells [25].
PLZ4 (amino acid sequence: cQDGRMGFc) was identified that could selectively bind to Bca jail cell lines and 3 primary Bca cells from human patients, but not to normal urothelial cells, cell mixtures from normal bladder specimens, fibroblasts, and blood cells [16]. After verifying the non-targeting properties of FITC, it can be connected to PLZ4 to discover cancer cells that shed urine.
Application in Treatment
The CLT1 peptide selected from the phage peptide library is a tumor homing peptide related to the clotted plasma of tumor stroma [40]. An in-depth understanding of peptides found that it can induce unfolded protein response and autophagy cell death in proliferating endothelial cells, thereby possessing antiangiogenic activity in vivo [41]. Besides, the cytotoxicity of fibronectin and CLT1 peptide is significantly increased afterward forming a complex. The P4 peptide, with its antitumor properties, also screened through the phage peptide library, binds to FGF9 to annul the aggressive phenotype induced by FGF9, including cell migration, invasion, and proliferation in vitro and inhibition of tumor growth in vivo. In research, FGF9 reduces the part of cisplatin-induced apoptosis to heighten drug resistance, and the antagonism of P4 to FGF9 tin can effectively enhance drug sensitivity [42].
Previous studies accept shown that the peptide at the C-terminus of p53 (p53C) can restore the binding and transactivation functions of the mutated p53-specific DNA sequence and cause p53-related tumor cell apoptosis [43]. p53C itself cannot enter tumor cells spontaneously to play a role. Incorporating p53C specifically into tumor cells is the direction of our research. Nonpolar and large macromolecules cannot pass through the prison cell membrane, but R11 tin transport hydrophilic substances and macromolecular proteins. R11 binds to p53C to deliver p53C to Bca cells. The results fully prove that R11 (R11-p53C) binding peptide can effectively target in situ and metastatic float tumor cells and inhibit tumor jail cell growth [42]. The R11-p53C peptide is a potential drug for bladder urothelial cancer treatment, whether for in situ or metastatic bladder tumors.
Liposome polyethylene glycol tin enhance the stability of particles in the float cavity and preclude particle aggregation, merely how to solve low retentivity in the treatment of bladder tumors remains to be explored. Teams have developed targeted preparations, such every bit micellar nanocarriers surface-modified PLZ4 ligand and liposome-linked RWFV peptides to form peptide biopolymers. The reward of these carriers is that they can encapsulate different therapeutic drugs and imaging agents. And it can be targeted to bladder tumor tissue, which can exist used for tumor imaging and flexible replacement of drugs [43].
In add-on to coupling with nanocarriers that encapsulate tumor chemotherapy drugs, peptides tin can likewise be directly coupled to antitumor drugs. The three lysine cores of NT4 provide other linking groups that tin exist used to connect other functional units [39]. Under the endoscope, the NT4 peptide is combined with a fluorescent grouping beginning, and the tumor is labeled and then combined with the chemotherapy drug. A simple "commutation" of functional units can achieve individualized treatment. Whether information technology is through nanocarriers or directly coupled with antitumor drugs, the tumor localization role of targeting peptides is used to internalize antitumor drugs into target tumor tissues, which not simply improves the level of intracellular medications but also reduces systemic side effects.
Conclusions and Future Perspectives
The targeted polypeptide is an amino acrid sequence that binds explicitly to unlike targets. It has become a hot inquiry topic in recent decades and has a wide range of applications in biomedicine. Compared with the existing urine exfoliated cell line examination, the targeting peptide for Bca has higher sensitivity. The combined use with cystoscope significantly improves the tumor detection rate of the cystoscope. Targeting peptides have practiced target tissue positioning and internalization capabilities. After beingness mixed with imaging agents, it can effectively find tumors that are not easy to notice in the early phase, and later replacing the treatment ligand, it plays the role of targeted therapy, reducing the systemic side effects of the drug. Although targeted peptides have many advantages, they also face up some problems. For example, how to maintain the stability of peptide molecules in the torso and control the rate of degradation. Although polypeptides made from D-amino acids are more stable than other structure amino acids, they are not suitable for specific receptor bounden applications due to the change in chirality. With the deepening of research, targeted peptides are expected to be used in the early on diagnosis of Bca, targeted therapy, and follow-upwardly examinations, and provide new methods for diagnosing and treating Bca.
In summary, well-nigh types of targeting peptides were screened out by involving specific types of cells equally models, thus lead to Their targeting approaches noneffective in covering some aspects of tumor-targeting mechanisms, that is to say, these peptides might exist that nonfunctional when exposed to tumor heterogeneity. Behaviors of targeting peptides and their complexes with cargos were different. The size and physiochemical properties of cargos might interfere with the targeting pathway. Current researches focus little on the role of targeting peptides in tumor promoter or inhibitor, exposing the unpredictable risk. Although the current targeting peptides nonetheless take shortcomings, their infinite potential deserves more attention. Once these targeted peptides are approved for clinical use, they will exist of great help to the diagnosis, treatment, and follow-up examination of Bca.
References
-
Justin, M., Mark, S., & Alfred, Westward. J., et al. (2020). Take a chance-adapted management of low-course bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). BJU International, 125, 497–505.
-
Kamat, A. Chiliad., Hegarty, P. Thousand., & Gee, J. R., et al. (2013). ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. European Urology, 63, 4–15.
-
Cai, Southward., Yan, J., & Xiong, H., et al. (2018). Investigations on the interface of nucleic acid aptamers and bounden targets. The Annotator, 143, 5317–5338.
-
Bayat, P., Nosrati, R., & Alibolandi, M., et al. (2018). SELEX methods on the route to protein targeting with nucleic acid aptamers. Biochimie, 154, 132–155.
-
Ryan, J. G., Wasser, J. S., & Adler, A. J., et al. (2016). Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: can we have our block and eat it as well? Proficient Opinion on Biological Therapy, 16, 655–674.
-
Kobus, T., Vykhodtseva, Northward., & Pilatou, M., et al. (2016). Condom validation of repeated blood-brain barrier disruption using focused ultrasound. Ultrasound in Medicine & Biological science, 42, 481–492.
-
Thiele, K., Ioannis, Z. K., & Zhang, Y. Z., et al. (2016). Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. J Control Release, 238, 281–288.
-
Smith, One thousand. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (New York, N.Y.), 228, 1315–1317.
-
Scott, J. K., & Smith, G. P. (1990). Searching for peptide ligands with an epitope library. Science (New York, N.Y.), 249, 386–390.
-
Wang, J., Tan, X., & Guo, Q., et al. (2020). FGF9 inhibition past a novel binding peptide has efficacy in gastric and bladder cancer per se and reverses resistance to cisplatin. Pharmacological Inquiry, 152, 104575.
-
Lee, South. Chiliad., Lee, E. J., & Hong, H. Y., et al. (2007). Targeting float tumor cells in vivo and in the urine with a peptide identified past phage brandish. Molecular Cancer Research, 5, 11–19.
-
Knowles, 50. M., Zewe, J., & Malik, 1000., et al. (2013). CLT1 targets bladder cancer through integrin α5β1 and CLIC3. Molecular Cancer Research, eleven, 194–203.
-
Yang, X., Zhang, F., & Luo, J., et al. (2016). A new non-muscle-invasive float tumor-homing peptide identified by phage display in vivo. Oncology Reports , 36, 79–89.
-
Ks, L., Se, S., & Em, H., et al. (1991). A new type of constructed peptide library for identifying ligand-binding activeness. Nature, 354, 82–84.
-
Lam, One thousand. Due south., Lehman, A. 50., & Song, A., et al. (2003). Synthesis and screening of "i-bead one-compound" combinatorial peptide libraries. Methods in Molecular Biology, 369, 298–322.
-
Lin, T. Y., Li, Y. P., & Liu, Q. Q., et al. (2016). Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for float cancer. Biomaterials, 104, 339–351.
-
Rao, B. D., Chakraborty, H., & Chaudhuri, A., et al. (2020). Differential sensitivity of pHLIP to ester and ether lipids. Chemistry and Physics of Lipids, 226, 104849.
-
Jlenia, B., Chiara, F., & Barbara, Fifty., et al. (2015). Neurotensin branched peptide equally a tumor-targeting agent for man bladder cancer. BioMed Research International, 2015, 1–7.
-
Pini, A., Falciani, C., & Bracci, L. (2008). Branched peptides as therapeutics. Current Poly peptide & Peptide Scientific discipline, 9, 468.
-
Khan, I. U., & Beck-Sickinger, A. G. (2008). Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents in Medicinal Chemical science, eight, 186.
-
Lundquist, J. T., & Dix, T. A. (1999). Preparation and receptor binding affinities of cyclic C-concluding neurotensin (eight-13) and (9-13) analogues. Bioorganic & Medicinal Chemistry Letters , 9, 2579–2582.
-
Young, L., Erin, K., & Scott, C., et al. (2017). Targeting and internalization of liposomes past float tumor cells using a fibronectin attachment protein-derived peptide–lipopolymer cohabit. Bioconjugate Chemistry , 28, 1481–1490.
-
Pugliese, A., Vidotto, Five., & Beltramo, T., et al. (2005). A review of HIV-one Tat protein biological effects. Cell Biochemistry & Function, 4, 223–227.
-
Vives, East., Brodin, P., & Lebleu, B. (1997). A truncated HIV-ane Tat poly peptide basic domain chop-chop translocates through the plasma membrane and accumulates in the cell nucleus. The Journal of Biological Chemistry, 272, 16010–16017.
-
Ding, C., Wu, K., & Wang, West., et al. (2017). Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer. Oncotarget, viii, 4718–4729.
-
Janessa, Due west., Eden, S. L., & Elizabeth, B., et al. (2020). pH-Dependent grafting of cancer cells with antigenic epitopes promotes selective antibiotic-mediated cytotoxicity. The Periodical of Medicinal Chemistry, 63, 3713–3722.
-
Anderson, M., Moshnikova, A., & Engelman, D. M., et al. (2016). Probe for the measurement of jail cell surface pH in vivo and ex vivo. Proceedings of the National Academy of Sciences of the United states, 113, 8177–8181.
-
Adochite, R. C., Moshnikova, A., & Golijanin, J., et al. (2016). Comparative Study of tumor targeting and biodistribution of pH (Low) insertion peptides (pHLIP(®) Peptides) conjugated with unlike fluorescent dyes. Molecular Imaging and Biology, eighteen, 686–696.
-
Chitrak, G., Yue, R., & Blake, Thou. (2018). Cooperative nonbonded forces command membrane binding of the pH-low insertion peptide pHLIP. The Biophysical Journal, 115, 2403–2412.
-
Jovana, G., Ali, A., & Anna, M., et al. (2016). Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo. Proceedings of the National Academy of Sciences of the United States of America , 113, 11829–11834.
-
Pablo, S., & Eliana, A. K. (2020). Targeting tumors using peptides. Molecules, 25, 808.
-
Wang, S. T., Chen, K. J., & Wu, T. H., et al. (2010). Photothermal effects of supramolecularly assembled golden nanoparticles for the targeted handling of cancer cells. Angewandte Chemie International Edition in English, 49, 3777–3781.
-
Dai, S., Zhou, Z., & Chen, Z. (2019). Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells, eight, 614–628.
-
Yu, J., Xu, Q. G., & Wang, Z. 1000., et al. (2018). Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. The Journal of Hepatology, 68, 1214–1227.
-
Zhang, Ten., Ibrahimi, O. A., & Olsen, S. K., et al. (2006). Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. The Periodical of Biological Chemical science, 281, 15694–15700.
-
Du, Y., Wang, L., & Wang, W., et al. (2018). Novel application of cell penetrating R11 peptide for diagnosis of float cancer. The Journal of Biomedical Nanotechnology, 14, 161–167.
-
Pankov, R. (2002). Fibronectin at a glance. The Journal of Cell Science, 115, 3861–3863.
-
Kim, J. H., Bae, C., & Kim, M. J., et al. (2020). A novel nucleolin-bounden peptide for cancer. Theranostics, 10, 9153–9171.
-
January, P., Darren, B. M., & Masanobu, K., et al. (2006). Peptides selected for binding to clotted plasma accrue in tumor stroma and wounds. Proceedings of the National Academy of Sciences of the United states of america of America, 103, 2800–2804.
-
Lynn, K. Thou., Gunjan, Yard., & Brian, H. Fifty., et al. (2012). CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis, 15, 115–129.
-
Lima, I., Navalkar, A., & Maji, Southward. Chiliad., et al. (2020). Biophysical characterization of p53 core domain aggregates. The Biochemical Journal, 477, 111–120.
-
Zhang, T. T., Wu, G. J., & Ding, C., et al. (2015). Inhibiting bladder tumor growth with a prison cell penetrating R11 peptide derived from the p53 C-terminus. Oncotarget, six, 37782–37791.
-
Wang, H., Ding, S., & Zhang, Z., et al. (2019). Cationic micelle: a promising nanocarrier for gene delivery with high transfection efficiency. The Journal of Gene Medicine, 21, e3101.
-
Roxin, A., & Zheng, G. (2012). Flexible or stock-still: a comparative review of linear and cyclic cancer-targeting peptides. Futurity Medicinal Chemistry, 4, 1601–1618.
-
Falciani, C., Brunetti, J., & Lelli, B., et al. (2013). Cancer selectivity of tetrabranched neurotensin peptides is generated by simultaneous binding to sulfated glycosaminoglycans and protein receptors. Medicinal Chemistry, 56, 5009–5018.
-
Falciani, C., Fabbrini, M., & Pini, A., et al. (2007). Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Molecular Cancer Therapeutics, 6, 2441–2448.
Author information
Affiliations
Corresponding writer
Ethics declarations
Conflict of interest
The author(s) alleged no potential conflicts of involvement with respect to the research, authorship, and/or publication of this commodity.
Additional data
Publisher'southward note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This commodity is licensed under a Artistic Commons Attribution four.0 International License, which permits use, sharing, accommodation, distribution and reproduction in any medium or format, as long as you give advisable credit to the original author(s) and the source, provide a link to the Artistic Commons license, and betoken if changes were fabricated. The images or other third party material in this article are included in the commodity's Creative Eatables license, unless indicated otherwise in a credit line to the material. If fabric is non included in the commodity'due south Creative Eatables license and your intended apply is not permitted by statutory regulation or exceeds the permitted use, yous will need to obtain permission straight from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Reprints and Permissions
Well-nigh this article
Cite this article
Zheng, B., Zhang, P., Wang, H. et al. Advances in Enquiry on Bladder Cancer Targeting Peptides: a Review. Cell Biochem Biophys 79, 711–718 (2021). https://doi.org/10.1007/s12013-021-01019-3
-
Accustomed:
-
Published:
-
Issue Engagement:
-
DOI : https://doi.org/x.1007/s12013-021-01019-3
Keywords
- Bladder tumor
- Peptides targeting
- Diagnosis
- Treatment
- Research progress
DOWNLOAD HERE
Posted by: colemanfrawing.blogspot.com